^
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: B - Late Trials
Ann Oncol - 1 week
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
VC
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
EP
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
CaT
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemVin
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GT
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GC
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + pemetrexed
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemCarbo
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
afatinib
Sensitive: A2 - Guideline
ALK fusion
Lung Non-Squamous Non-Small Cell Cancer
brigatinib
Sensitive: A2 - Guideline
ALK fusion
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive: A2 - Guideline
EGFR T790M
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
EGFR L858R
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: B - Late Trials
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
camrelizumab
Sensitive: B - Late Trials
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: B - Late Trials
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: B - Late Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: B - Late Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: B - Late Trials
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
EGFR L858R
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
crizotinib
Sensitive: B - Late Trials
MHC-II overexpression + PD-L1 negative
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: B - Late Trials
MHC-II overexpression + PD-L1 underexpression
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: B - Late Trials
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ceritinib
Sensitive: B - Late Trials
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib + ABBV-399
Sensitive: C2 – Inclusion Criteria
MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
ABBV-399
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive: C2 – Inclusion Criteria
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
crizotinib
Sensitive: C2 – Inclusion Criteria
ROS1 rearrangement
Lung Non-Squamous Non-Small Cell Cancer
crizotinib
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: C3 – Early Trials
EGFR T790M
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 inhibitor
Resistant: C3 – Early Trials
KEAP1 mutation
Lung Non-Squamous Non-Small Cell Cancer
docetaxel
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
docetaxel
Resistant: C3 – Early Trials
KEAP1 mutation
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Resistant: C3 – Early Trials
EGFR mutation + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
KEAP1 mutation
Lung Non-Squamous Non-Small Cell Cancer
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
STK11 mutation + KEAP1 mutation
Lung Non-Squamous Non-Small Cell Cancer
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
MET positive
Lung Non-Squamous Non-Small Cell Cancer
erlotinib + ABBV-399
Sensitive: C3 – Early Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
X-396
Sensitive: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + CP-675206
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab
Resistant: C3 – Early Trials
EGFR expression
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive: C3 – Early Trials
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + afatinib
Sensitive: C3 – Early Trials
CEACAM5 overexpression
Lung Non-Squamous Non-Small Cell Cancer
SAR408701
Sensitive: C3 – Early Trials
MGAM mutation
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: C3 – Early Trials
NRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive: C3 – Early Trials
MAP2K1 mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive: C3 – Early Trials
NKX2-1 expression + PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab + abemaciclib
Sensitive: C3 – Early Trials
KRAS G12V
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: C3 – Early Trials